Acute Effects of GLP-1 on Renal Hemodynamics

• Status: Completed
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study investigates the hypothesis, that GLP-1's suppression of ANG II and natriuretic action increase medullary perfusion and decrease oxygen consumption, leading to higher tissue oxygenation.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Rigshospitalet, Denmark
• Collaborator: Department of Cardiovascular and Renal Research, University of Southern Denmark
• Treatments: Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• Normal health demonstrated by medical examination.

• Normal values for fasting plasma glucose, total cholesterol, triglyceride, HDL, LDL, creatinine, AST, ALT and electrolyte concentrations.

Exclusion Criteria:

• Immunosuppressive treatment for the previous 12 months.

• Alcohol abuse.

• Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists that, in the opinion of the investigator, may interfere with glucose metabolism.

• Use of lithium.

• Medical treatment that affects insulin secretion or cardiovascular efficacy goals.

• Liver disease (ALT> 2 x normal value).

• Renal impairment (creatinine> 130 µM and / or albuminuria).

• Severe claustrophobia.

• MRI incompatible foreign bodies.